These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36463417)

  • 1. Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids.
    de Wit K; Beuers U; Mukha A; Stigter ECA; Gulersonmez MC; Ramos Pittol JM; Middendorp S; Takkenberg RB; van Mil SWC
    Liver Int; 2023 Mar; 43(3):649-659. PubMed ID: 36463417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice.
    Cheng J; Krausz KW; Tanaka N; Gonzalez FJ
    Toxicol Sci; 2012 Oct; 129(2):456-68. PubMed ID: 22790967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin is a gut-specific human pregnane X receptor activator.
    Ma X; Shah YM; Guo GL; Wang T; Krausz KW; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2007 Jul; 322(1):391-8. PubMed ID: 17442842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells.
    Mencarelli A; Migliorati M; Barbanti M; Cipriani S; Palladino G; Distrutti E; Renga B; Fiorucci S
    Biochem Pharmacol; 2010 Dec; 80(11):1700-7. PubMed ID: 20816942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer.
    Cheng J; Fang ZZ; Nagaoka K; Okamoto M; Qu A; Tanaka N; Kimura S; Gonzalez FJ
    J Pharmacol Exp Ther; 2014 Dec; 351(3):559-67. PubMed ID: 25277138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.
    Cheng J; Shah YM; Ma X; Pang X; Tanaka T; Kodama T; Krausz KW; Gonzalez FJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):32-41. PubMed ID: 20627999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells.
    Mencarelli A; Renga B; Palladino G; Claudio D; Ricci P; Distrutti E; Barbanti M; Baldelli F; Fiorucci S
    Eur J Pharmacol; 2011 Oct; 668(1-2):317-24. PubMed ID: 21806984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function.
    Hirota SA
    Mini Rev Med Chem; 2015; 16(3):206-17. PubMed ID: 26202186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis.
    Terc J; Hansen A; Alston L; Hirota SA
    Eur J Pharm Sci; 2014 May; 55():12-9. PubMed ID: 24486481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EFFECT OF PREGNANE XENOBIOTIC RECEPTOR ACTIVATION ON INFLAMMATORY BOWEL DISEASE TREATED WITH RIFAXIMIN.
    Wan YC; Li T; Han YD; Zhang HY; Lin H; Zhang B
    J Biol Regul Homeost Agents; 2015; 29(2):401-10. PubMed ID: 26122229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnane X receptor as a target for treatment of inflammatory bowel disorders.
    Cheng J; Shah YM; Gonzalez FJ
    Trends Pharmacol Sci; 2012 Jun; 33(6):323-30. PubMed ID: 22609277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diethylstilbestrol-scaffold-based pregnane X receptor modulators.
    Hodnik Ž; Tomašič T; Smodiš D; D'Amore C; Mašič LP; Fiorucci S; Kikelj D
    Eur J Med Chem; 2015 Oct; 103():551-62. PubMed ID: 26408814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2153-60. PubMed ID: 25352391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid.
    Owen BM; Milona A; van Mil S; Clements P; Holder J; Boudjelal M; Cairns W; Parker M; White R; Williamson C
    Drug Metab Dispos; 2010 Jan; 38(1):143-9. PubMed ID: 19797606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
    Shawcross DL; Thabut D; Amodio P
    J Hepatol; 2023 Aug; 79(2):266-268. PubMed ID: 37178732
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.